Free tool
FAERS Monitor: Slynd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211367 or its brand name (Slynd, Drospirenone). Reports on generic versions are filed under their own applications.
Reports
5,416
Serious
1,061
20% of reports
Hospitalization
307
Death reported
24
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intermenstrual bleeding1,691
- amenorrhoea863
- heavy menstrual bleeding634
- dysmenorrhoea389
- product dose omission issue251
- nausea231
- product use in unapproved indication225
- headache201
- intentional dose omission199
- wrong technique in product usage process181
- fatigue169
- menstruation irregular162
- product prescribing issue157
- off label use156
- anxiety139
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 8 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 10 |
| 2017 | 5 |
| 2018 | 20 |
| 2019 | 43 |
| 2020 | 95 |
| 2021 | 131 |
| 2022 | 402 |
| 2023 | 936 |
| 2024 | 1,094 |
| 2025 | 1,316 |
| 2026 | 1,327 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intermenstrual bleedingSignal | 1,691 | 1683.8 | 1600.9 | 1,983,602 |
| heavy menstrual bleedingSignal | 634 | 294.3 | 272.7 | 172,082 |
| amenorrhoeaSignal | 863 | 200.9 | 188.7 | 163,189 |
| dysmenorrhoeaSignal | 389 | 117.4 | 106.5 | 43,477 |
| product prescribing issueSignal | 157 | 28.2 | 24.1 | 4,064 |
| intentional dose omissionSignal | 199 | 27.3 | 23.8 | 4,986 |
| menstruation irregularSignal | 162 | 23.6 | 20.3 | 3,471 |
| product use in unapproved indicationSignal | 225 | 3.5 | 3.1 | 409 |
| wrong technique in product usage processSignal | 181 | 3.5 | 3.0 | 319 |
| product dose omission issueSignal | 251 | 3.3 | 2.9 | 409 |
| anxiety | 139 | 1.9 | 1.6 | 59 |
| headache | 201 | 1.2 | 1.1 | 10 |
| nausea | 231 | 1.1 | 1.0 | 4 |
| fatigue | 169 | 0.8 | 0.7 | 5 |
| off label use | 156 | 0.7 | 0.6 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.